| Adjuvant chemotherapy in locally advanced cervical cancer after treatment with concomitant chemoradiotherapy–Room for improvement? TB Jelavić, BP Miše, A Strikic, M Ban, E Vrdoljak Anticancer research 35 (7), 4161-4165, 2015 | 32 | 2015 |
| Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation … BP Miše, TB Jelavic, A Strikic, D Hrepic, K Tomic, W Hamm, S Tomic, ... International Journal of Gynecologic Cancer 25 (2), 2015 | 25 | 2015 |
| Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer-single institution experience. M Ban, J Viculin, S Tomic, V Capkun, A Strikic, BP Mise, I Utrobicic, ... Neoplasma 63 (5), 761-767, 2016 | 8 | 2016 |
| Determining the immunohistochemical expression of GLUT1 in renal cell carcinoma using the HSCORE method M Ogorevc, A Strikic, S Zekic Tomas Biomedical reports 15 (4), 1-6, 2021 | 4 | 2021 |
| Optimal follow-up of ovarian cancer patients E Vrdoljak, BP Miše, TB Jelavić, S Tomić, D Šundov, A Strikić memo-Magazine of European Medical Oncology 8, 57-61, 2015 | 3 | 2015 |
| The Effect of GLUT1 and HIF-1α Expressions on Glucose Uptake and Patient Survival in Non-Small-Cell Lung Carcinoma J Kokeza, A Strikic, M Ogorevc, N Kelam, M Vukoja, I Dilber, ... International journal of molecular sciences 24 (13), 10575, 2023 | 1 | 2023 |
| Differential expression of HIF1A and its downstream target VEGFA in the main subtypes of renal cell carcinoma and their impact on patient survival A Strikic, J Kokeza, M Ogorevc, N Kelam, M Vukoja, P Dolonga, SZ Tomas Frontiers in Oncology 13, 2023 | 1 | 2023 |
| Uloga inhibitora CDK4/6 u liječenju hormonski ovisnoga metastatskog raka dojke negativnog na HER-2 M Ban, A Strikić, B Petrić Miše, E Vrdoljak Liječnički vjesnik 141 (1-2), 33-39, 2019 | 1 | 2019 |
| Results of treatment of muscle-invasive bladder cancer in University Hospital of Split: 2014-2021 Ž Saratlija Novaković, T Boban, T Boraska Jelavić, T Omrčen, M Šitum, ... 14th Croatian oncology congress, 125-125, 2021 | | 2021 |
| Hematotoxicity od cyclin dependent kynases 4/6 (CDK4/6) inhibitors palbociclib and ribocyclib during first 2 cycles of treatment of metastatic breast cancer–a restropective … A Majić, I Urlić, M Pancirov, A Paparella-Karaman, A Strikić, M Ban, ... 13. hrvatski onkološki kongres, 99-99, 2020 | | 2020 |
| Role of CDK4/6 inhibitors in metastatic hormon positive HER2 negative breast cancer treatment M Ban, A Strikić, B Petrić Miše, E Vrdoljak Liječnički vjesnik 141 (1-2), 33-39, 2019 | | 2019 |
| Correlation of the progression free survival after 1st treatment line (PFS1) with overall survival (OS) changes in metastatic breast cancer (MBC): Retrospective cohort study M Ban, Ž Bajić, M Buljubašić, I Dražić, B Petrić Miše, A Strikić, M Božić, ... 14th CEOC, 53-57, 2018 | | 2018 |
| Differences in the overall survival (OS) of primary and secondary metastatic breast cancer (MBC) patients: A retrospective study M Ban, I Dražić, M Buljubašić, Ž Bajić, B Petrić Miše, A Strikić, M Božić, ... 14th CEOC, 50-52, 2018 | | 2018 |
| Hand-foot syndrome as a potential biomarker for the effectiveness of sunitinib in renal cell carcinoma T Omrčen, D Ledina, T Boraska Jelavić, M Boban, B Petrić Miše, S Mikuš, ... CEOC 2014, 1-1, 2014 | | 2014 |
| Single institution experiance in adjuvant treatment of HER 2 positive breast cancer patients E Vrdoljak, J Viculin, A Strikić, D Hrepić, M Ban 9th Central European Oncology Congress-CEOC, 2013 | | 2013 |
| New approaches in cancer treatment E Vrdoljak, L Bošković, B Petrić Miše, T Boraska Jelavić, J Viculin, ... Medix: specijalizirani medicinski dvomjesečnik 18 (100), 2012 | | 2012 |
| Novosti u onkološkom liječenju E Vrdoljak, L Bošković, B Petrić Miše, T Boraska Jelavić, J Viculin, ... Medix (Zagreb) 100, 179-187, 2012 | | 2012 |
